Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients

British Journal of Radiology

Volumn 85, Issue 1018, 2012, Pages 1420-1426

  Thornton, E ^a   Howard, S A ^a   Jagannathan, J ^a   Krajewski, K M ^a   Shinagare, Atul ^a   O'Regan, K ^a   Cleary, J M ^a   Ramaiya, N H ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; INFLIXIMAB; IPILIMUMAB; OXALIPLATIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ANASTOMOSIS; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER THERAPY; CARCINOMATOUS PERITONITIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLITIS; COLONOSCOPY; COLOSTOMY; COMPUTER ASSISTED TOMOGRAPHY; CYSTOGRAPHY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; ENTEROCOLITIS; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; HEMATURIA; HIP PAIN; HUMAN; INTESTINE FISTULA; INTESTINE PERFORATION; KIDNEY METASTASIS; LIVER METASTASIS; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MORBIDITY; OVARY CARCINOMA; PNEUMOPERITONEUM; PRIMARY TUMOR; RECTUM CARCINOMA; SMALL INTESTINE OBSTRUCTION;

AGED; COLITIS; FEMALE; GASTROENTERITIS; HUMANS; INTESTINAL DISEASES; INTESTINAL FISTULA; INTESTINAL PERFORATION; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASMS; PNEUMATOSIS CYSTOIDES INTESTINALIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84866860162     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/19815818     Document Type: Article

References (13)

1. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009;10:559-68.
2. Coriat R, Ropert S, Mir O, Billemont B, Chaussade S, Massault PP, et al. Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. Invest New Drugs 2011;29:1090-3.
3. Messersmith WA, Jimeno A, Jacene H, Zhao M, Kulesza P, Laheru DA, et al. Phase 1 trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer 2010;9:297-304.
4. Parithivel K, Ramaiya N, Jagannathan JP, O'Regan K, Krajewski K, Fisher D, et al. Everolimus- and temsirolimus-associated enteritis: report of three cases. J Clin Oncol 2011;29:e404-6.
5. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283-9. (Pubitemid 46630658)
6. Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 2008;19:577-82. (Pubitemid 351325682)
7. Saif MW. Managing bevacizumab-related toxicities in patients with colorectal cancer. J Support Oncol 2009;7:245-51.
8. Richardson DL, Backes FJ, Hurt JD, Seamon LG, Copeland LJ, Fowler JM, et al. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? Gynecol Oncol 2010;118:47-51.
9. Walraven M, Witteveen PO, Lolkema MP, van Hillegersberg R, Voest EE, Verheul HM. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis 2011;14:135-41.
10. Asmis TR, Chung KY, Teitcher JB, Kelsen DP, Shah MA. Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity. Invest New Drugs 2008;26:95-6.
11. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
12. Spigel DR, Burris HA 3rd, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011;29:2582-9.
13. Chow H, Jung A, Talbott J, Lin AM, Daud AI, Coakley FV, et al. Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences. J Comput Assist Tomogr 2011;35:86-90.